tbuckley/cabot-search huggingface dataset:
CORONARY ARTERY CALCIUM AND ESTIMATED CARDIOVASCULAR DISEASE RISK IN FIVE RACIAL/ETHNIC GROUPS LIVING IN THE US: THE MEDIATORS OF ATHEROSCLEROSIS IN SOUTH ASIANS LIVING IN AMERICA (MASALA) STUDY AND THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
Authors: Jaideep Patel, Zeina Dardari, Miguel Cainzos-Achirica, Parag Joshi, Namratha Kandula, Matthew Budoff, Joseph Yeboah, Moyses Szklo, Eliseo Guallar, Roger Blumenthal, Alka Kanaya, Michael Blaha
Journal: Journal of the American College of Cardiology (2017)
Hormone receptor expression and risk of recurrence in patients with high-risk endometrial carcinoma treated with chemotherapy.
Authors: Olivia Claire Barrett, Omer L. Burnett, Michael G. Conner, Yufeng Li, Jacob Michael Estes, Jennifer F. De Los Santos
Journal: Journal of Clinical Oncology (2012)

e15502 Background: Poor long-term survival in high-risk endometrial cancer patients attests to a need for new therapeutic strategies. The prevalence of estrogen (ER) and progesterone receptors (PR) among high-risk endometrial carcinomas has not been systematically studied and is a target to which individualized therapies may be tailored. Methods: 41 women with high grade, stage III/IV and/or aggressive histology endometrial cancer who received post-hysterectomy chemotherapy were identified. Patient, tumor and treatment characteristics were recorded. Immunohistochemical staining of ER and PR was scored on a 0-4 scale incorporating intensity and extent of expression. Receptor-positivity was defined as a score of &gt;= 2. Univariate and multivariate logistic regression analysesand the Cox proportional hazards model were performed to examine hormone receptor expression and recurrence risk. Results: Median age at surgery was 59 years (range 34-79). Median follow up time was 39 months (range 1-82). Recurrence occurred in 21 women (51%) with median time to first recurrence of 19 months (range 1-71). 22 cancers (54%) were ER+ and 21 (51%) PR+. Median ER and PR expression was 2 and 2, respectively (range 0-4). While ER and PR were not independent factors for recurrence, on multivariate logistic regression analysis ER and PR as continuous values showed recurrence associated with greater ER expression (p = 0.0836) and lesser PR expression (p = 0.0986). Cox proportional hazards model supported the association between increasing ER and decreasing PR with shorter recurrence free survival (p=0.0034, p = 0.0021). An increase in ER score of 1 corresponded to a hazard ratio (HR) of 2.647 (95% CI 1.38-5.08); an increase in PR score of 1 corresponded to a HR of 0.362 (0.19-0.693). Conclusions: More than 50% of high-risk endometrial cancers in this small retrospective cohort receiving cytotoxic chemotherapy expressed positive hormone receptors. Multivariate analyses of hormone receptors suggest increased recurrence with discordant expression of ER and PR. Further investigation is warranted to verify whether differential hormone receptor expression predicts poorer response to cytotoxic systemic therapy.
LOS PACIENTES DE RIESGO INTERMEDIO CON 3 – 4 ADENOMAS Y AL MENOS UNO ≥10&lt; 20MM PRESENTAN UN PERFIL DE RIESGO DIFERENCIADO EN EL CRIBADO DE CANCER COLORRECTAL
Authors: E Pérez-Cuadrado Robles, E Torrella Cortés, JL Rodrigo Agudo, S Chacón Martinez, A López Martín, H Hallal, B Martínez Andrés, JF Sánchez Melgarejo, P Esteban Delgado, E Pérez-Cuadrado Martinez, F Pérez-Riquelme
Journal: Endoscopy (2015)

Introducción: Las guías europeas clasifican a los pacientes sometidos a una colonoscopia de cribado en riesgo intermedio (RI) de cáncer colorrectal ante: 3 – 4 adenomas, ≥1 entre 10 – 19 mm, ≥1 con componente velloso y/o carcinoma in situ/displasia de alto grado. Se ha demostrado que el riesgo de adenoma avanzado (RAA) difiere significativamente en pacientes con RI y alto riesgo (AR). Sin embargo, el grupo RI es muy heterogéneo y el RAA para cada uno de estos hallazgos podría ser diferente.
Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial
Authors: S. Halabi, O. Sartor, D. Petrylak, C. N. Sternberg, J. A. Witjes, M. Noursalehi, T. J. McKearn, M. J. George
Journal: Journal of Clinical Oncology (2009)

5150 Background: It has been shown in chemotherapy naïve patients that PFS is a statistically significant predictor of OS. The main objectives of this analysis were to explore whether PFS at 3-months is a predictor of OS and to investigate the dependence between PFS and OS in CRPC men who failed first line chemotherapy. Methods: Data from SPARC, a multi-national, randomized, double-blind trial, comparing satraplatin + prednisone vs placebo + prednisone in 950 CRPC patients were used. For the purpose of this analysis, the two treatment groups were combined. PFS was defined as the time from date of randomization to date of first progression (bone scan progression, radiographic, soft-tissue progression, symptomatic, or skeletal related events) or death, whichever occurred first. PFS at 3-months was defined as a binary variable in the following manner: if a patient experienced any type of progression at or before 3-months then this was considered as an event. If a patient did not progress at 3 months then he was censored. Landmark analysis of PFS at 3-months predicting OS was performed. In addition, the proportional hazards model was used to assess the significance effect of PFS at 3-months in predicting OS adjusting for the stratification factors. Finally, the association between OS and PFS was investigated using a statistic that estimates Kendall's tau measure of association for bivariate time to event outcomes subject to censoring. Results: 477 (56%) men progressed at 3-months of 853 men who were alive at 3-months. The median survival times were 34.5 weeks (95% CI = 30.8–40.4) and 78.7 weeks (95% CI=70.1–83.2, p-value&lt;0.001) respectively in men who did and did not experience progression at 3-months. Men who had progressed at 3-months were more likely to die than men who did not progress (hazard ratio = 2.16, 95% CI =1.84 -2.55, p-value &lt; 0.001). The dependence between PFS and OS was 0.29 (95% confidence limits = 0.24–0.33, p-value &lt; 0.00001). Conclusions: PFS at 3-months predicts OS. The results of this large retrospective analysis show moderate, but strong statistical dependence between PFS and OS. Future studies are needed to assess the clinical relevance of the distinct components of progression. [Table: see text]
A Phase II Trial of R-FM (Rituximab, Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (90Y-IT) for Untreated Follicular Lymphoma (FL) Patients.
Authors: Pier Luigi Zinzani, Monica Tani, Alessandro Broccoli, Enrico Derenzini, Alessandro Pulsoni, Amalia De Renzo, Stefano Fanti, Mariapaola Fina, Letizia Gandolfi, Cinzia Pellegrini, Vittorio Stefoni, Michele Baccarani
Journal: Blood (2009)
PREVALENT DIGOXIN USE IS NOT ASSOCIATED WITH INCREASED RISK OF DEATH OR HOSPITALIZATION IN AMBULATORY HEART FAILURE PATIENTS WITH A REDUCED EJECTION FRACTION
Authors: Andrew P. Ambrosy, Ankeet Bhatt, Amanda Stebbins, Lisa Wruck, Stephen Greene, Marat Fudim, William Kraus, Christopher O'Connor, Ileana Pina, David Whellan, Robert Mentz
Journal: Journal of the American College of Cardiology (2017)
PLATELET AGGREGABILITY, COAGULATION, FIBRINOLYSIS AND INFLAMMATION IN PATIENTS WITH CORONARY ARTERY DISEASE AND PREVIOUS CEREBROVASCULAR ISCHEMIC EVENT
Authors: Carlos José Dornas Gonçalves Barbosa, Renata Barreiros, Andre Franci, Remo Furtado, Flavia Arantes, Célia Strunz, Rocha Tania, Jose Antonio F. Ramires, Roberto Kalil-Filho, Jose Nicolau
Journal: Journal of the American College of Cardiology (2017)
Double blind, randomized, placebo-controlled, multi-center,phase II dose ranging study to assess the antifibrotic activityof farglitazar in chronic hepatitis C infection.
Authors: John G McHutchinson, Zachary D Goodman, Hala R Maklouf, Maribel Rodriguez-Torres, Mitchell L Shiffman, Don C Rockey, Petr Husa, Wan-Long Chuang
Journal: Hepatology (2008)
Phase I trial and pharmacokinetic (PK) study of satraplatin in children and young adults with refractory solid tumors including brain tumors.
Authors: Srivandana Akshintala, Leigh Marcus, Katherine E. Warren, Robert F. Murphy, Wendy J. Goodspeed, Anne Goodwin, Carmen C. Brewer, Christopher Zalewski, Kelly A. King, AeRang Kim, Brigitte C. Widemann
Journal: Journal of Clinical Oncology (2013)

2554 Background: Satraplatin is an orally bioavailable platinum analog. Based on pre-clinical activity (IC 50 0.02-8 µg/ml) including activity in cisplatin resistant cell lines, and clinical activity without neuro-, nephro-, or ototoxicity in adults with refractory tumors, we developed a phase 1 trial to determine the toxicities, maximum tolerated dose (MTD), and PKs of satraplatin in children with refractory solid tumors. Methods: Satraplatin (10 and 50 mg capsules) was administered orally once daily on days 1 - 5 of a 28 day cycle to cohorts of 3-6 patients (pts) at 60 mg/m 2 /dose (DL 1) and 80 mg/m 2 /dose (DL 2). Plasma ultrafiltrate (PUF) platinum was measured using atomic absorption spectroscopy during cycle 1 for PK analysis. Results: 9 pts [5 male, 4 female, median age 17 years (range 8-19)] with malignant glioma (n=4), ependymoma (n=2), medulloblastoma (n=1), osteosarcoma (n=1), or hepatoblastoma (n=1) received 1-10+ cycles (median 2). The MTD was exceeded at DL 2 as 2/4 pts had dose limiting toxicities (DLT) of delayed and prolonged myelosuppression (grade 3 thrombocytopenia, n=1; grade 3-4 neutropenia, n=2). 0/5 pts at DL 1 had DLTs. Grade 1 ototoxicity was seen in 1 pt at cycle 10. Non-DLTs included myelosuppression, gastrointestinal toxicities, fatigue, headache, liver enzyme elevation, and electrolyte abnormalities. No objective responses were observed, but 1 pt with gliomatosis cerebri has had radiographic stable disease through cycle 10+. Satraplatin mean exposure (AUC) and peak concentration (C max ) were similar at both dose levels [day 1 PUF AUC 0-24h 1.22 ± 0.55 µg/ml*h at DL1 (n=3), 1.02 ± 0.45 µg/ml*h at DL2 (n=3); C max 0.17 ± 0.08 µg/ml at DL 1 (n=3), 0.16 ± 0.05 µg/ml at DL 2 (n=3)]. Terminal half-life was 14 ± 6 h and apparent clearance was 76 ± 29 L/h (n=6). Conclusions: The MTD of oral satraplatin in children with solid tumors is 60 mg/m 2 /dose daily x 5 q28 days. The toxicity profile was similar to adults, and delayed myelosuppression was DLT. Satraplatin exposure appears higher in pediatric pts compared to adults (PUF AUC 0-24h 0.25-0.47 µg/ml*h at 60-80 mg/m 2 /dose). DL 1 will be expanded to gain additional experience regarding toxicities and PKs in a broader age range. Clinical trial information: NCT01259479.
Effect of a novel small molecule yk-4-279 on the "undruggable" target EWS-FLI1.
Authors: Jeffrey Toretsky, S. Ellen Gamble, Philip J. Monroe, S. Peter Hong, Stephen J. Summer, Aykut Uren, Sung-Hyeok Hong
Journal: Journal of Clinical Oncology (2013)

10042 Background: Chimeric transcription factors are ideal anti-cancer targets since they are only present in tumor cells, however they are often considered ‘undruggable’ proteins. The EWS-FLI1 fusion protein of Ewings sarcoma (ES) has been validated as an anticancer target both alone and as a partner of RNA Helicase A (RHA). Our prior work identified (S)-YK-4-279 as an enantiospecific inhibitor of EWS-FLI1 by blocking the interaction with RHA leading to apoptosis. Methods: Pharmacokinetic (PK) models of YK-4-279 for both IP and IV administration were developed in SD rats and BL6 mice using drug concentrations determined by a validated LC-MS/MS assay. Xenograft ES mice validated PK models with apoptosis measured by TUNEL. A novel nude rat ES orthotopic xenograft was created give (S)-YK-4-279 by continuous IV infusion. Results: SD rat and BL6 mouse PK modeling demonstrated an elimination half-life t1/2 of 30 minutes following IV administration; SCID/bg mice demonstrated 50% faster clearance. A survival curve showed maximal killing of ES cells between 1 and 3 microM YK-4-279 over a 40-hour time course. Clonogenic replating assays demonstrated 3 microM exposure for 72 hours would reduce replating efficiency of ES cells to less than 0.01%. SCID/bg ES xenografts treated with IP YK-4-279 BID for 6 doses showed a 25-35% enantiospecific tumor regression with an average 3.5-fold increase in apoptosis. A nude rat xenograft, with continuous infusion (S)-YK-4-279 maintained an average level of 4.9 microM in plasma for 26 days. The ES1 xenograft tumor responded in 4 of 5 animals, with complete regression in 2 of 5, without toxicity. Conclusions: A combination of PK modeling and cell culture studies confirmed that (S)-YK-4-279 is required to be present at low microM levels for optimal tumor response. These levels were achieved in a novel rat xenograft of ES in order to demonstrate an important proof of efficacy. These PK-driven xenograft therapy studies are useful for development of PK models to compare YK-4-279 levels with functional activity. Targeting ‘undruggable’ protein-protein interactions with small molecules is novel and the ES model shows that continuous IV infusion may be required for optimal clinical translation.
Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
Authors: John Francis Seymour, Matthew Steven Davids, John M. Pagel, Brad S. Kahl, William G. Wierda, Thomas P. Miller, John F. Gerecitano, Thomas J. Kipps, Mary Ann Anderson, David C.S. Huang, David E. Darden, Lori A. Gressick, Cathy E. Nolan, Jianning Yang, Todd A. Busman, Alison M. Graham, Elisa Cerri, Sari H. Enschede, Rod A. Humerickhouse, Andrew Warwick Roberts
Journal: Journal of Clinical Oncology (2013)

7018 Background: Targeting BCL-2 is a promising strategy for treating CLL, including disease refractory to fludarabine (F), or with (del(17p). ABT-199 is a selective BCL-2 inhibitor with &gt;500-fold higher affinity for BCL-2 (K i &lt;0.10 nM) than for BCL-X L (K i =48 nM). Methods: Objectives of this Ph I dose-escalation study include evaluations of safety, pharmacokinetics and preliminary efficacy of ABT-199 in patients (pts) with R/R CLL. A single oral dose was given followed by 6 days off drug, before continuous once daily dosing. After cohort 1, the initial dose was reduced and daily dosing modified to include a 2 or 3 step dose-escalation to the target dose for each cohort. Results: As of January 11, 2013, 56 pts have been enrolled; median age 67 y (range 36-86); 41 males; median 3.5 prior therapies (range 1-10). 16 (29%) had del(17p) and 18 (32%) F-refractory CLL. Median follow up is 6.3 months (range 0.03-16.5); 7 pts have been on study for more than 1 yr. 13 pts discontinued; 7 due to PD, 6 for other reasons: tumor lysis syndrome (TLS; 2), other illness (2), thromboembolic event (1), consent withdrawal (1). The most common non-hematological AEs (&gt;15% pts) were nausea (36%), diarrhea (30%), fatigue (25%), upper respiratory tract infection (23%), and cough (16%). Grade 3/4 AEs occurring in &gt; 5 pts were neutropenia 21(38%), thrombocytopenia 6 (11%) and TLS 5 (9%). TLS occurred in 3/3 pts in cohort 1 and 2/53 pts with the modified stepped dosing schedule (DLTs). Additionally, 1 fatal AE occurred within 48 hrs of dose-escalation to 1200 mg in a pt with laboratory evidence of TLS (DLT). 46 of 54 pts (85%) evaluable for efficacy achieved a response to ABT-199; 7 (13%) a CR or CR with incomplete count recovery and 39 (72%) a PR (30 confirmed by consecutive scans). 14/16 (88%) and 12/16 (75%) of pts with del(17p) and F-refractory CLL, respectively, achieved at least a PR. Conclusions: ABT-199 is highly active achieving a 85% overall response rate in R/R CLL, independent of high risk markers such as del(17p) and F-refractory disease. Additional dosing and scheduling modifications are currently being explored to minimize the risk of TLS. Clinical trial information: NCT01328626.
TIME TO ACUTE CARE AMONG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION IN CHINA: A REPORT FROM CHINA PATIENT-CENTERED EVALUATIVE ASSESSMENT OF CARDIAC EVENTS PROSPECTIVE STUDY OF ACUTE MYOCARDIAL INFARCTION
Authors: Wenchi Guan, Arjun K. Venkatesh, Xueke Bai, Si Xuan, Jing Li, Xin Zheng, Li Xi, Haibo Zhang, Frederick Masoudi, John Spertus, Harlan Krumholz, Lixin Jiang
Journal: Journal of the American College of Cardiology (2017)
Association of HMGB1 Polymorphisms with Outcome After Allogeneic Hematopoietic Cell Transplantation.
Authors: Brian Kornblit, Tania Nicole Masmas, Søren Lykke Petersen, Hans O Madsen, Carsten Heilmann, Lone Schejbel, Henrik Sengeloev, Klaus Müller, Peter Garred, Lars Vindelov
Journal: Blood (2009)
AUTOMATED DETECTION OF MITRAL VALVE ANNULAR AND LEAFLET GEOMETRY: ECHOCARDIOGRAPHY AND CT COMPARISON
Authors: Margret Bratanoff, Ben Lin, Tawai Ngernsritrakul, Mohammed T. Essa, Helene Houle, David Hur, Rachel E. Kaplan, Hamid Mojibian, Lissa Sugeng
Journal: Journal of the American College of Cardiology (2017)
A phase II study of pazopanib (P) in patients (Pts) with localized renal cell carcinoma (RCC) to enable partial nephrectomy (PN).
Authors: Adriana L. Alvarez, Elizabeth R. Plimack, Robert Dreicer, Timothy D. Gilligan, Jorge A. Garcia, Paul Elson, Steven C. Campbell, Venkatesh Krishnamurthi, Jihad Kaouk, Amr Farouk Fergany, Robert G. Uzzo, Andrew J. Stephenson, Laura S. Wood, David Y. T. Chen, Brian I. Rini
Journal: Journal of Clinical Oncology (2014)

4522 Background: PN is the preferred surgical approach for localized renal masses in order to preserve renal function, but is not always possible due to tumor size/location. VEGF-targeted agents such as a Paz have shown safety and anti-tumor effect in primary RCC tumors, thus allowing for potential conversion to PN in patients who would otherwise require radical nephrectomy (RN). Methods: Pts with treatment-naïve, localized clear cell RCC meeting one or more of the following criteria were enrolled on a prospective phase II trial: estimated GFR < 30 mL/min if RN was performed, risk of morbidity > 30% with PN due to tumor anatomy (e.g. proximity to renal vasculature) or Renal Nephrometry Score (RNS) 10-12. Paz 800 mg po daily was given continuously with repeat imaging at 8 and 16 weeks, and PN performed if/when adequate tumor reduction per primary surgeon discretion. The primary endpoint was rate of conversion to PN (Ho 15% vs. Ha 40%; p=0.05; power 90%). Results: Twenty-three pts were enrolled; 85% male, median age 64, 70% PS 0, 60% had baseline GFR<60. 90% of pts were able to undergo PN; 2 pts required RN. The median time from the start of Paz to surgery was 10.6 weeks (range, 5.4-18.9). Median baseline tumor size was 7.6 cm (range, 3.7-10.7cm); median RNS was 11 (range, 8-12); 82% were considered highly complex by RNS. 95% of tumors shrank (median decrease 1.8 cm; range 0.2-3.8); median change relative to baseline -26% (range, +6.3% to -40.9%). RECIST PR rate was 32%. RNS decreased in 81% of tumors and complexity group decreased in 43%. The estimated median post-PN change in GFR relative to baseline (ml/minute/1.73 m2 per 2005 MDRD equation) was an 18.0% decrease (range, -46% to +21%). No unexpected surgical complications or unexpected Paz toxicity was observed. Conclusions: Neoadjuvant Paz leads to tumor downsizing in clear cell RCC tumors and allows for PN in a subset of patients in whom RN is otherwise required. Clinical trial information: NCT01158521.
Distribution and clinical significance of CTLA4, PD-1 and PD-L1 in peripheral blood of patients with small-cell lung cancer.
Authors: Ying Cheng, Hui Li, Ying Liu, Lixia Ma, Xianhong Liu, Yan Liu, Jingjing Liu, Shuang Zhang
Journal: Journal of Clinical Oncology (2015)

7574 Background: Cytotoxic T lymphocyte associated antigen 4 (CTLA4), programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are key components of immune checkpoints and the most attractive targets in immunotherapy for cancer. These antigens are abundant in tumor samples, however their distribution and clinical value in liquid biopsy (such as blood) of small-cell lung cancer (SCLC) patients remains unclear. Methods: 60 healthy and 230 chemotherapy-naïve patients with SCLC were recruited. Venous blood samples were collected prior to chemotherapy (baseline) and after the second cycle of chemotherapy (2nd cycle), and flow cytometry was used to analyze the level of CTLA4, PD-1 or PD-L1 with or without CD3, CD4, CD8 or CD25. Immunohistochemistry was used to detect PD-L1 expression in SCLC cell line H446. Results: Cells of CTLA4+, CD3+CTLA4+ and CD4+CTLA4+ in SCLC were (1.06±1.51)%, (4.12±5.30)% and (3.95±2.80)%, respectively and PD-1+, CD3+PD-1+, and CD4+PD-1+ were (7.96±3.38)%, (25.86±8.49) % and (20.92±8.31) %, which were not different from those in control. However, level of CD4+CD25+CTLA4+cells were higher in SCLC than that in control, (6.77±4.71)% vs (1.91±1.27)%, P< 0.001 and CD8+ PD1+cells were less in SCLC than that in control, (11.49±5.23) % vs (22.56±4.21)%, P< 0.001, neither of which were associated with age, sex, smoke or disease stage. Level of CD4+CD25+CTLA4+cells was dropped to (5.77±3.77)% after 2nd cycle compare to that at baseline (P= 0.04), but level of CD8+PD1+cells was not altered. Interim analysis showed neither the level of CD4+CD25+CTLA4+ nor CD8+PD1+cells before or after treatment was related to progression–free survival or overall survival of patients. Although PD-L1 was highly expressed in H446, it was rarely found in peripheral blood. Conclusions: We for the first time showed that CTLA4 was highly expressed in regulatory T cells and PD-1 decreased in CD8 in peripheral blood of SCLC patients, suggesting their unique mechanisms involved in immune regulation. CD4+CD25+CTLA4+level changed after treatment implies its potential role in predicting treatment efficacy.
OUTCOME-BASED COST ANALYSIS OF TRANSFEMORAL TRANSCATHETER AORTIC VALVE REPLACEMENT USING FASCIA ILIACA COMPARTMENT BLOCK AND MINIMALIST CONSCIOUS SEDATION APPROACH VERSUS GENERAL ANESTHESIA
Authors: Wei Lau, Francis Shannon, George S. Hanzel, Marc Sakwa, Amr E. Abbas, Robert Safian, Ivan Hanson, Steve Almany, Alessandro Vivacqua
Journal: Journal of the American College of Cardiology (2017)
IMPAIRED LEFT VENTRICULAR LONGITUDINAL FUNCTIONAL RESERVE IN PATIENTS WITH PSORIATIC ARTHRITIS: A LOW-LEVEL BICYCLE ERGOMETER EXERCISE TEST
Authors: Qing Shang, Hua Li, Lai-Shan Tam, John E. Sanderson, Ching-Han Priscilla Wong, Cheuk-Man Yu, Brian Tomlinson
Journal: Journal of the American College of Cardiology (2017)
IMPACT OF DIABETES MELLITUS ON ANTITHROMBOTIC MANAGEMENT PATTERNS AND LONG-TERM CLINICAL OUTCOMES IN PATIENTS WITH ACUTE CORONARY SYNDROME: INSIGHT FROM THE EPICOR ASIA STUDY
Authors: Yi Li, Shaoyi Guan, Mingzi Guan, Xiaozeng Wang, Jing Li, Heyang Wang, Yong Huo, Frans Van de Werf, Jie Jiang, Ana Maria Vega, Nobuya Hayashi, Yaling Han
Journal: Journal of the American College of Cardiology (2017)
INCREASED CONCENTRATIONS OF SOLUBLE ST2 INDEPENDENTLY PREDICT CARDIAC AND TOTAL MORTALITY BUT NOT NON-FATAL CARDIOVASCULAR EVENTS IN STABLE CORONARY HEART DISEASE PATIENTS: 13-YEAR FOLLOW-UP OF THE KAROLA STUDY
Authors: Veronika Sanin, Vanessa Pfetsch, Andrea Jaensch, Dhayana Dallmeier, Ute Mons, Hermann Brenner, Wolfgang Koenig, Dietrich Rothenbacher, Deutsches Herzzentrum München
Journal: Journal of the American College of Cardiology (2017)
Dysregulation of SHFM1, a Novel Target for Prevention of Genomic Instability in Myeloma, Is Associated with Epigenetic Changes at Specific CpG Sites
Authors: Masood Shammas, Subodh Kumar, Jagannath Pal, Puru Nanjappa, Mehmat Samur, Maria Gkotzamanidou, Jialan Shi, Nikhil C. Munshi
Journal: Blood (2014)
MICRORNA-26A FROM HYPOXIC HUMAN MESENCHYMAL STEM CELLS: DERIVED MICROVESICLES ENHANCE CARDIAC CONDUCTION FOLLOWING MYOCARDIAL INFARCTION
Authors: Hyelim Park, Hyewon Park, Hyoeun Kim, Seung-Hyun Lee, Shanyu Cui, Hui-Nam Pak, Moon-Hyoung Lee, Boyoung Joung
Journal: Journal of the American College of Cardiology (2017)